Our approach
Supporting future-builder leaders and assisting SMEs/ETIs building the future in their development and transfer projects.
Press
SMEs and ETIs to accelerate their growth trajectory.
Support
SMEs/ETIs in their transition towards more sustainable business models
Contribute
to the emergence of European and international champions
Facilitate
the transfer of family-run and family-owned SMEs/ETIs.
Our raison d'être
GENEO's raison d'être is to provide the real economy with positive finance that reconciles performance and meaning.
Time management
Bring from the serenity by the control of time, for to the cycles cycles and adapt to need of every needs.
Human capital
Promote activation and increase of capital capital as lever decisive of creation of value at providing a support operational support and support and and of expertise.
Positive impact
Support growth of positive impact of every company and its transition to to models business business models.
Sharing
Share the value created with all of parties stakeholders, for give à every generation the means of its ambitions.
Our strengths
Evergreen
An investment company with an unlimited lifespan, GENEO offers tailor-made capital, capable of following ambitious strategies over time and acting countercyclically.
Growth book
The "Growth Book" is GENEO's operational tool, to identify and prioritize with each company the key issues of executing the business plan, and to provide tailor-made operational and human support through our teams, our experts and the GENEO Community.
GENEO community
Entrepreneur Capital also offers unique support from our shareholders, including more than 250 entrepreneurs and families, for greater experience sharing and business networking, in France and internationally.
Key figures
+ OF
740M€
UNDER MANAGEMENT
(FEBRUARY 2025)
70
EXPERTS
REFERENCED CARNETS DE CROISSANCE
7
BUSINESS PARTNERS
24
EQUAL NUMBERS OF EMPLOYEES
MULTIDISCIPLINARY AND COMMITTED
(MARCH 2025)
+1800
NET JOBS CREATED SINCE 2021
+260
INVESTORS
MEMBERS OF THE GENEO COMMUNITY
31
COMPANIES INVESTED AND SUPPORTED
OF WHICH 30 IN PORTFOLIO(AT 05/31/2025)
46%
OF 2024 SALES GENERATED BY PORTFOLIO COMPANIES OUTSIDE FRANCE
2
OFFICES
IN PARIS AND LYON
114
ACQUISITIONS
BY INVESTED COMPANIES, INCLUDING 60 INTERNATIONAL ACQUISITIONS
700k€
DONATED TO OUR ENDOWMENT FUND SINCE 2019
GENEdico
News
Sterimed group becomes independent, restructures and strengthens its shareholder base
STERIMED, a French company and world leader in medical packaging, announces the finalization of a capital restructuring agreement led by its management, and the implementation of a new strategic plan.
Exclusive GENEO Capital Entrepreneur survey: the 2025 Heroes' Compass
Exclusive GENEO Capital Entrepreneur Survey
The "2025 Heroes' Compass": In the face of geopolitical uncertainties, French growth mid-sized companies are staying the course.
New organization for investor relations and the Community
GENEO Capital Entrepreneur announces a new organization for its Investor Relations and Community division.